North America & Europe Age-related Macular Degeneration Therapeutics Market to Benefit from Increasing Geriatric Population
Age-related macular degeneration causes loss in the center of the field of vision. According to Bright Focus Foundation, around 11 million people in the U.S. have some form of age-related macular degeneration and the number is expected to double to nearly 22 million by 2050. Such scenario is expected to aid in growth of the North America & Europe age-related macular degeneration therapeutics market . Age-related macular degeneration is a common condition — it’s a leading cause of vision loss for people age 50 and older. According to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Thus, increasing geriatric population is a major contributor in growth of the North America & Europe age-related macular degeneration therapeutics market. Dry age-related macular degeneration is a common eye disorder among people over 50. It causes blurred or reduced central vision, due to thinning of the macula (MAK-u-luh). Dry age-related mac...